3 hours ago
1
Devonyu/iStock via Getty Images
Pfizer (NYSE:PFE) and Astellas Pharma (OTCPK:ALPMF) announced on Tuesday that their jointly developed antibody-drug conjugate, Padcev, in combination with Merck’s (NYSE:MRK) PD-1 inhibitor, Keytruda, reached the main goals in a late-stage trial for certain patients with bladder cancer.
Citing interim
English (US) ·